Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26683625 | 1.00 | CRBN (0.43) | CRBNDDB1HTR2CHTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL29507035 | 0.99 | CRBN (0.42) | CRBNDDB1HTR2CHTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL25337439 | 0.99 | CRBN (0.42) | CRBNDDB1HTR2CHTR1AHTR2A | |
| SCHEMBL31134437 | 0.91 | CRBN (0.41) | CRBNDDB1HTR2CHTR1AHTR2A | |
| SCHEMBL30688293 | 0.88 | DDB1 (0.42) | CRBNDDB1HTR1AHTR2ADRD2 | |
| SCHEMBL26684089 | 0.88 | DDB1 (0.42) | CRBNDDB1HTR1AHTR2ADRD2 | |
| SCHEMBL26684220 | 0.85 | DDB1 (0.40) | CRBNDDB1HTR1AHTR2ADRD2 | |
| SCHEMBL29507006 | 0.85 | DDB1 (0.40) | CRBNDDB1HTR1AHTR2ADRD2 | |
| SCHEMBL30688294 | 0.84 | DDB1 (0.39) | CRBNDDB1HTR2ADRD2 | |
| SCHEMBL26683716 | 0.84 | DDB1 (0.39) | CRBNDDB1HTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | CRBN 2312/4885DDB1 4162/4885HTR2C 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.